Literature DB >> 19688595

Association between nonalcoholic fatty liver disease and coronary artery calcification.

Chien-Hua Chen1, Chiu-Kue Nien, Chi-Chieh Yang, Yung-Hsiang Yeh.   

Abstract

BACKGROUND: Both nonalcoholic fatty liver disease (NAFLD) and coronary artery disease (CAD) are closely related to many metabolic disorders. Multislice computed tomography (MSCT) is a reliable noninvasive method in demonstrating coronary plaque. However, the association between coronary artery calcium (CAC) score and NAFLD remains controversial. AIMS: The aim of this study is to evaluate the association between CAC score and NAFLD.
METHODS: This retrospective study enrolled 295 consecutive asymptomatic subjects who had both coronary angiography by MSCT and hepatobiliary imaging during self-paid physical check-ups.
RESULTS: NAFLD was found in 41% of the enrolled 295 subjects; gall bladder stones were found in 10.8%, and CAC > 100 with moderate-high risk of CAD was found in 12.9% of subjects. Male gender (odds ratios (OR), 3.087; 95% confidence intervals (CI), 1.092-8.729), increased age (OR, 1.108; 95% CI, 1.067-1.151), diabetes mellitus (DM) (OR, 2.968; 95% CI, 1.129-7.803), and NAFLD (OR, 2.462; 95% CI, 1.065-5.691) were the independent factors that increased the risk of CAC > 100 in binary logistic regression. The prevalence of NAFLD also increased with the severity of CAC score (<or=100, 38.1%; 101-400, 58.3%; >400, 64.3%; P = 0.03).
CONCLUSIONS: Besides the traditional risk factors, such as male gender, increased age, and DM, NAFLD was also associated with moderate to high risk of CAD (CAC > 100).

Entities:  

Mesh:

Year:  2009        PMID: 19688595     DOI: 10.1007/s10620-009-0935-9

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  46 in total

1.  Quantification of coronary artery calcium using ultrafast computed tomography.

Authors:  A S Agatston; W R Janowitz; F J Hildner; N R Zusmer; M Viamonte; R Detrano
Journal:  J Am Coll Cardiol       Date:  1990-03-15       Impact factor: 24.094

2.  Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease.

Authors:  T Heitzer; T Schlinzig; K Krohn; T Meinertz; T Münzel
Journal:  Circulation       Date:  2001-11-27       Impact factor: 29.690

3.  Prevalence and risk factors of gallstone disease in an adult population of Taiwan: an epidemiological survey.

Authors:  Chien-Hua Chen; Min-Ho Huang; Jee-Chun Yang; Chiu-Kue Nien; Gina Doskey Etheredge; Chi-Chieh Yang; Yung-Hsiang Yeh; Hurng-Sheng Wu; Der-Aur Chou; Sen-Kou Yueh
Journal:  J Gastroenterol Hepatol       Date:  2006-11       Impact factor: 4.029

4.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

5.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

6.  Prevalence of noncalcified coronary plaques by 64-slice computed tomography in patients with an intermediate risk for significant coronary artery disease.

Authors:  Jörg Hausleiter; Tanja Meyer; Martin Hadamitzky; Adnan Kastrati; Stefan Martinoff; Albert Schömig
Journal:  J Am Coll Cardiol       Date:  2006-06-22       Impact factor: 24.094

7.  Influence of a lipid-lowering therapy on calcified and noncalcified coronary plaques monitored by multislice detector computed tomography: results of the New Age II Pilot Study.

Authors:  Christof Burgstahler; Anja Reimann; Torsten Beck; Axel Kuettner; Dorothee Baumann; Martin Heuschmid; Harald Brodoefel; Claus D Claussen; Andreas F Kopp; Stephen Schroeder
Journal:  Invest Radiol       Date:  2007-03       Impact factor: 6.016

8.  Evaluation of vulnerable coronary plaques and non-alcoholic fatty liver disease (NAFLD) by 64-detector multislice computed tomography (MSCT).

Authors:  Satoshi Akabame; Masahide Hamaguchi; Ki-Ichiro Tomiyasu; Muhei Tanaka; Yoshiko Kobayashi-Takenaka; Koji Nakano; Yohei Oda; Toshikazu Yoshikawa
Journal:  Circ J       Date:  2008-04       Impact factor: 2.993

9.  Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.

Authors:  Masahide Hamaguchi; Takao Kojima; Noriyuki Takeda; Chisato Nagata; Jun Takeda; Hiroshi Sarui; Yutaka Kawahito; Naohisa Yoshida; Atsushi Suetsugu; Takahiro Kato; Junichi Okuda; Kazunori Ida; Toshikazu Yoshikawa
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

10.  Prediction of coronary atherosclerotic disease with liver transaminase level.

Authors:  Peyman Adibi; Masoumeh Sadeghi; Majid Mahsa; Golnaz Rozati; Masood Mohseni
Journal:  Liver Int       Date:  2007-09       Impact factor: 5.828

View more
  40 in total

1.  Dietary supplementation with methyl donors reduces fatty liver and modifies the fatty acid synthase DNA methylation profile in rats fed an obesogenic diet.

Authors:  P Cordero; A M Gomez-Uriz; J Campion; F I Milagro; J A Martinez
Journal:  Genes Nutr       Date:  2012-05-31       Impact factor: 5.523

2.  Nonalcoholic fatty liver disease is associated with coronary artery calcification.

Authors:  Donghee Kim; Su-Yeon Choi; Eun Ha Park; Whal Lee; Jin Hwa Kang; Won Kim; Yoon Jun Kim; Jung-Hwan Yoon; Sook Hyang Jeong; Dong Ho Lee; Hyo-suk Lee; Joseph Larson; Terry M Therneau; W Ray Kim
Journal:  Hepatology       Date:  2012-07-02       Impact factor: 17.425

3.  Associations between nonalcoholic fatty liver disease and subclinical atherosclerosis in middle-aged adults: the Coronary Artery Risk Development in Young Adults Study.

Authors:  Lisa B VanWagner; Hongyan Ning; Cora E Lewis; Christina M Shay; John Wilkins; J Jeffrey Carr; James G Terry; Donald M Lloyd-Jones; David R Jacobs; Mercedes R Carnethon
Journal:  Atherosclerosis       Date:  2014-06-10       Impact factor: 5.162

Review 4.  Non-alcoholic fatty liver disease - the heart of the matter.

Authors:  Haneen Azzam; Stephen Malnick
Journal:  World J Hepatol       Date:  2015-06-08

Review 5.  Cardiac abnormalities in patients with nonalcoholic fatty liver disease : Insights from auxiliary examinations.

Authors:  Yu Dong; Guangsen Li
Journal:  Herz       Date:  2019-09-19       Impact factor: 1.443

6.  The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Mahmoud Al Rifai; Michael G Silverman; Khurram Nasir; Matthew J Budoff; Ron Blankstein; Moyses Szklo; Ronit Katz; Roger S Blumenthal; Michael J Blaha
Journal:  Atherosclerosis       Date:  2015-02-07       Impact factor: 5.162

Review 7.  The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis.

Authors:  Mangesh R Pagadala; Arthur J McCullough
Journal:  Clin Liver Dis       Date:  2012-06-27       Impact factor: 6.126

Review 8.  Nonalcoholic fatty liver disease and the coronary artery disease.

Authors:  Sombat Treeprasertsuk; Francisco Lopez-Jimenez; Keith D Lindor
Journal:  Dig Dis Sci       Date:  2010-05-13       Impact factor: 3.199

Review 9.  Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease.

Authors:  Stefano Ballestri; Amedeo Lonardo; Stefano Bonapace; Christopher D Byrne; Paola Loria; Giovanni Targher
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

10.  Fatty liver, abdominal adipose tissue and atherosclerotic calcification in African Americans: the Jackson Heart Study.

Authors:  Jiankang Liu; Solomon K Musani; Aurelian Bidulescu; J Jeffery Carr; James G Wilson; Herman A Taylor; Caroline S Fox
Journal:  Atherosclerosis       Date:  2012-08-10       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.